Bicycle Therapeutics plc Research and Development Expense
Bicycle Therapeutics plc (BCYC) reported Research and Development Expense of $41.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- Bicycle Therapeutics plc research and development expense for the quarter ending 2026-06-30 was $41.16M, a 42.05% decline year-over-year.
- Bicycle Therapeutics plc research and development expense for the quarter ending 2026-03-31 was $48.90M, a 17.20% decline year-over-year.
- Bicycle Therapeutics plc research and development expense for the quarter ending 2025-12-31 was $51.77M, a 4.00% increase year-over-year.
- Bicycle Therapeutics plc research and development expense for the quarter ending 2025-09-30 was $58.43M, a 21.05% increase year-over-year.
- Bicycle Therapeutics plc research and development expense for fiscal 2025 was $240.28M, a 38.92% increase from fiscal 2024.
- Bicycle Therapeutics plc research and development expense for fiscal 2024 was $172.97M, a 10.52% increase from fiscal 2023.
- Bicycle Therapeutics plc research and development expense for fiscal 2023 was $156.50M, a 91.76% increase from fiscal 2022.
- Bicycle Therapeutics plc research and development expense for fiscal 2022 was $81.61M, a 81.84% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.16M 10-Q · filed 2026-07-30 | $90.06M 10-Q · filed 2026-07-30 | $141.83M derived: sum of 3 quarters · filed 2026-07-30 | $200.26M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $48.90M 10-Q · filed 2026-04-30 | $100.67M derived: sum of 2 quarters · filed 2026-04-30 | $159.10M derived: sum of 3 quarters · filed 2026-04-30 | $230.13M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $51.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $110.20M derived: sum of 2 quarters · filed 2026-03-17 | $181.22M derived: sum of 3 quarters · filed 2026-07-30 | $240.28M 10-K · filed 2026-03-17 |
| 2025-09-30 | $58.43M 10-Q · filed 2025-10-30 | $129.46M derived: sum of 2 quarters · filed 2026-07-30 | $188.51M 10-Q · filed 2025-10-30 | $238.29M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $71.03M 10-Q · filed 2026-07-30 | $130.09M 10-Q · filed 2026-07-30 | $179.87M derived: sum of 3 quarters · filed 2026-07-30 | $228.13M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $59.06M 10-Q · filed 2026-04-30 | $108.84M derived: sum of 2 quarters · filed 2026-04-30 | $157.10M derived: sum of 3 quarters · filed 2026-04-30 | $197.16M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $49.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $98.04M derived: sum of 2 quarters · filed 2026-03-17 | $138.10M derived: sum of 3 quarters · filed 2026-03-17 | $172.97M 10-K · filed 2026-03-17 |
| 2024-09-30 | $48.27M 10-Q · filed 2025-10-30 | $88.32M derived: sum of 2 quarters · filed 2025-10-30 | $123.19M 10-Q · filed 2025-10-30 | $167.88M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $40.06M 10-Q · filed 2025-08-08 | $74.92M 10-Q · filed 2025-08-08 | $119.62M derived: sum of 3 quarters · filed 2026-03-17 | $159.49M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $34.86M 10-Q · filed 2025-05-01 | $79.56M derived: sum of 2 quarters · filed 2026-03-17 | $119.43M derived: sum of 3 quarters · filed 2026-03-17 | $159.15M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $44.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $84.56M derived: sum of 2 quarters · filed 2026-03-17 | $124.28M derived: sum of 3 quarters · filed 2026-03-17 | $156.50M 10-K · filed 2026-03-17 |
| 2023-09-30 | $39.87M 10-Q · filed 2024-10-31 | $79.59M derived: sum of 2 quarters · filed 2024-10-31 | $111.80M 10-Q · filed 2024-10-31 | $136.52M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $39.72M 10-Q · filed 2024-08-06 | $71.93M 10-Q · filed 2024-08-06 | $96.65M derived: sum of 3 quarters · filed 2025-02-25 | $119.40M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $32.21M 10-Q · filed 2024-05-02 | $56.93M derived: sum of 2 quarters · filed 2025-02-25 | $79.68M derived: sum of 3 quarters · filed 2025-02-25 | $99.54M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $24.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $47.47M derived: sum of 2 quarters · filed 2025-02-25 | $67.33M derived: sum of 3 quarters · filed 2025-02-25 | $81.61M 10-K · filed 2025-02-25 |
| 2022-09-30 | $22.75M 10-Q · filed 2023-11-02 | $42.61M derived: sum of 2 quarters · filed 2023-11-02 | $56.89M 10-Q · filed 2023-11-02 | $69.85M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $19.85M 10-Q · filed 2023-08-03 | $34.14M 10-Q · filed 2023-08-03 | $47.09M derived: sum of 3 quarters · filed 2024-02-20 | $57.61M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $14.28M 10-Q · filed 2023-05-04 | $27.24M derived: sum of 2 quarters · filed 2024-02-20 | $37.75M derived: sum of 3 quarters · filed 2024-02-20 | $49.48M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $12.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $23.47M derived: sum of 2 quarters · filed 2024-02-20 | $35.19M derived: sum of 3 quarters · filed 2024-02-20 | $44.88M 10-K · filed 2024-02-20 |
| 2021-09-30 | $10.51M 10-Q · filed 2022-11-03 | $22.23M derived: sum of 2 quarters · filed 2022-11-03 | $31.92M 10-Q · filed 2022-11-03 | $41.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $11.72M 10-Q · filed 2022-08-04 | $21.41M 10-Q · filed 2022-08-04 | $31.47M derived: sum of 3 quarters · filed 2023-02-28 | $38.84M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $9.69M 10-Q · filed 2022-05-05 | $19.75M derived: sum of 2 quarters · filed 2023-02-28 | $27.11M derived: sum of 3 quarters · filed 2023-02-28 | $35.07M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $10.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $17.42M derived: sum of 2 quarters · filed 2023-02-28 | $25.38M derived: sum of 3 quarters · filed 2023-02-28 | $33.15M 10-K · filed 2023-02-28 |
| 2020-09-30 | $7.36M 10-Q · filed 2021-11-04 | $15.32M derived: sum of 2 quarters · filed 2021-11-04 | $23.09M 10-Q · filed 2021-11-04 | $29.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $7.96M 10-Q · filed 2021-08-05 | $15.73M 10-Q · filed 2021-08-05 | $22.38M derived: sum of 3 quarters · filed 2022-03-01 | $28.46M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $7.77M 10-Q · filed 2021-05-06 | $14.42M derived: sum of 2 quarters · filed 2022-03-01 | $20.50M derived: sum of 3 quarters · filed 2022-03-01 | $27.04M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $12.73M derived: sum of 2 quarters · filed 2022-03-01 | $19.26M derived: sum of 3 quarters · filed 2022-03-01 | $25.54M 10-K · filed 2022-03-01 |
| 2019-09-30 | $6.08M 10-Q · filed 2020-11-05 | $12.62M derived: sum of 2 quarters · filed 2020-11-05 | $18.89M 10-Q · filed 2020-11-05 | $25.38M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $6.54M 10-Q · filed 2020-08-05 | $12.81M 10-Q · filed 2020-08-05 | $19.31M derived: sum of 3 quarters · filed 2021-03-11 | $24.95M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $6.28M 10-Q · filed 2020-05-07 | $12.77M derived: sum of 2 quarters · filed 2021-03-11 | $18.41M derived: sum of 3 quarters · filed 2021-03-11 | $23.33M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $12.13M derived: sum of 2 quarters · filed 2021-03-11 | $17.05M derived: sum of 3 quarters · filed 2021-03-11 | $20.76M 10-K · filed 2021-03-11 |
| 2018-09-30 | $5.64M 10-Q · filed 2019-11-07 | $10.56M derived: sum of 2 quarters · filed 2019-11-07 | $14.27M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $4.92M 10-Q · filed 2019-08-08 | $8.63M 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $11.87M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |